Vulvar Diseases Overview

Principles

Definition

Vulvar diseases is a specialized area within clinical medicine and pathology dedicated to the systematic investigation, diagnosis, and management of diverse conditions affecting the vulva. This field encompasses the study of inflammatory, infectious, neoplastic, and dermatological disorders of the external female genitalia, critical for addressing women's reproductive and overall health needs.

Ontological type

Management Strategies

Diagnostic Workup

Clinical Presentation

Key developments

Key Figures

Clinical-Epidemiologic Systematization era

During 1949–1978, vulvar disease research organized around cross-disciplinary gynecologic–venereal teams and systematic case series. Representative authors of the period (clinician-epidemiologists and pathologists) advanced standardized recognition and staging by applying cytologic, histopathologic, and serologic methods to connect clinical patterns with etiologies. These figures promoted interinstitutional collaboration, typified by classification schemes and pathology-driven decision-making for inflammatory, infectious, and neoplastic vulvar conditions. Although no formal author registry is available for this era, the collective output shaped early diagnostic frameworks and therapeutic strategies that anchored subsequent vulvar disease research.

HPV-Driven Personalized Care era

Susan Cu-Uvin [1] is a clinician-scientist active during the HPV-Driven Personalized Care era, affiliated with Rockefeller University [2] and Harvard University [3]. Her key contribution in this era includes the 2001 paper Prevalence, Incidence, and Type-Specific Persistence of Human Papillomavirus in Human Immunodeficiency Virus (HIV)–Positive and HIV–Negative Women [4], which advanced understanding of HPV type distribution and host factors, informing risk stratification and targeted surveillance. Building on that study, her work helped bridge virology with clinical decision making in vulvar care by integrating viral status with pathology-informed risk assessment to guide prevention and adjuvant strategies [4]. Together, these contributions illustrate how virologic insights from this era laid the groundwork for personalized vulvar care and influenced subsequent immunologic and vaccine-oriented approaches.

Standardization and Surveillance era

Joel M. Palefsky [1], affiliated with Harvard University [3] and the University of California, San Francisco [4] during the Standardization and Surveillance era, is a leading figure in vulvar disease research. His key contributions include co-leading the Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations [6] and The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated Lesions [7], which established a unified terminology that enables cross-center reporting, prognostic stratification, and guideline-driven diagnostic pathways. Teresa M. Darragh [2], connected with the College of American Pathologists [5] and Harvard University [3], contributed to the same standardization efforts during this era. Her contributions, as co-author across the same standardization papers [6] and [7], advanced harmonized nomenclature for vulvar HPV-associated lesions, facilitating consistent reporting and risk-based surveillance crucial for the era's public health frameworks.